Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2014 Jan 29:10:63-74.
doi: 10.2147/VHRM.S55298. eCollection 2014.

Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey

Robert J Petrella  1 , Guy Tremblay  2 , Guy De Backer  3 , Dawn P Gill  4 ; POWER survey Study Group
Collaborators, Affiliations
Observational Study

Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey

Robert J Petrella et al. Vasc Health Risk Manag. .

Abstract

Purpose/introduction: The Canadian Hypertension Education Program (CHEP) has identified blood pressure (BP) control as a key target for an overall reduction in cardiovascular disease risk. The POWER survey (Physicians' Observational Work on Patient Education According to their Vascular Risk) used Framingham methodology to investigate the impact of an angiotensin-receptor-blocker-based regimen on arterial BP and total coronary heart disease (CHD) risk in a subset of patients recruited in Canada.

Methods: 309 Canadian practices screened for patients with either newly diagnosed or uncontrolled mild/moderate hypertension (sitting systolic blood pressure [SBP] >140 mmHg with diastolic blood pressure [DBP] <110 mmHg). Treatment comprised eprosartan 600 mg/day with add-on antihypertensive therapy after 1 month if required. The primary efficacy variable was change in SBP at 6 months; the secondary variable was the absolute change in the Framingham 10-year CHD risk score.

Results: 1,385 patients were identified, of whom 1,114 were included in the intention-to-treat (ITT) cohort. Thirty-eight point four percent of ITT patients were managed with monotherapy at 6 months, versus 35.2% and 13.7% with two-drug or multiple-drug therapy, respectively. SBP in the ITT cohort declined 22.4 (standard deviation [SD] 14.8) mmHg and DBP declined 10.5 (SD 10.3) mmHg during that time. The absolute mean Framingham score declined 2.1 (SD 3.1) points with significant age and sex variation (P<0.001) and differences between the various Framingham methods used.

Discussion/conclusion: Primary care physicians were able to use a strategy of BP lowering and CHD risk assessment to achieve significant reductions in BP and Framingham-assessed CHD risk. The effect size estimate of the different Framingham methods varied noticeably; reasons for those differences warrant further investigation.

Keywords: angiotensin-receptor blocker; blood pressure; hypertension; observational study.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient disposition. Notes: *Patients may appear in more than one exclusion category. **Reasons other than those described in the protocol (eg, newly-diagnosed hypertension, an inability to tolerate other antihypertensive medication, or a lack of response to current antihypertensive medication). Abbreviations: SBP, systolic blood pressure; V1, baseline; ITT, intention to treat; PP, per protocol.
Figure 2
Figure 2
Baseline Framingham CHD risk status, according to methodology. Abbreviation: CHD, coronary heart disease.
Figure 3
Figure 3
Shifts in Framingham CHD risk distribution during treatment. Notes: (A) n=892 and 811 for baseline and end of study, respectively. (B) n=540 and 424 for baseline and end of study, respectively. (C) n=546 and 427 for baseline and end of study, respectively. Abbreviation: CHD, coronary heart disease.
Figure 4
Figure 4
Aggregate shift in Framingham CHD risk distribution during treatment. Abbreviation: CHD, coronary heart disease.
See this image and copyright information in PMC

References

    1. Robitaille C, Dai S, Waters C, et al. Diagnosed hypertension in Canada: incidence, prevalence and associated mortality. CMAJ. 2012;184(1):E49–E56. - PMC - PubMed
    1. Daskalopoulou SS, Khan NA, Quinn RR, et al. Canadian Hypertension Education Program The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol. 2012;28:270–287. - PubMed
    1. Padwal RS, Hemmelgarn BR, Khan NA, et al. Canadian Hypertension Education Program The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol. 2009;25:279–286. - PMC - PubMed
    1. Grover SA, Hemmelgarn B, Joseph L, Milot A, Tremblay G. The role of global risk assessment in hypertension therapy. Can J Cardiol. 2006;22:606–613. - PMC - PubMed
    1. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847. - PubMed

Publication types

MeSH terms